```json
{
"content": [
{
"type": "paragraph",
"content": "The Monoamine Oxidase Inhibitor Drugs industry trends over the past 18 months reveal a strategic pivot toward precision psychiatry. In March 2024, Neurocrine Biosciences paid $185 million upfront to acquire Diurnal’s late-stage oral selegiline patch platform, betting on once-weekly dosing to outmaneuver generic competition. Simultaneously, Delpor and Otsuka formed an alliance (Q2 2024) to combine Delpor’s titanium-implant MAOI reservoir with Otsuka’s digital adherence sensors, aiming for a 12-month, data-rich depot formulation."
},
{
"type": "paragraph",
content: "Regulators are accelerating reviews for reversible MAO-A agents: the FDA granted Breakthrough Therapy status to Confluence’s CX-1502 (rilmenidine analog) in January 2024 after Phase IIb showed a 4.2-point superiority over selegiline on the MADRS scale. Post-COVID, payers are reimbursing genotype-guided dosing of tranylcypromine under new CPT codes introduced April 2024, catalyzing a 27% rise in companion diagnostic prescriptions. Venture funding reflects the optimism—Kynexis closed a $92 million Series B (Dec 2023) to advance brain-penetrant MAO-B/HDAC dual inhibitors, while Atai Life Sciences spun out Maiya to explore psychedelic-augmented MAOIs, securing $40 million in June 2023."
}
]
}
```
